IP Library Granted Patent US 7,244,749
Granted Patent B2
US 7,244,749 · App. 10/765,236 · Granted Jul 17, 2007

Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,244,749
App. No.
10/765,236
Granted
Jul 17, 2007
Kind
B2
Abstract

The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.

Claims (6)

1. A method of lowering plasma concentration of a lipoprotein Lp(a) in a mammal, comprising administering to the mammal a composition of biochemical substances consisting essentially of ascorbic acid, ascorbyl palmitate, beta-, gamma-, delta-tocopherol-mix, beta-carotene, biotin, calcium ascorbate, calcium glycinate, α-carotene, lutein, zea-cryptoxanthin, cholecalciferol, chromium glycinate, citrus bioflavonoids, coenzyme Q 10, copper glycinate, cyanocobalamin, d-alpha-tocopherol, d-calcium pantothenate, dicalcium phosphate, folic acid, inositol, L-arginine, L-carnitine, L-cysteine, L-lysine, L-proline, L-seleonmethionine, magnesium ascorbate, magnesium glycinate, manganese chelate, molybdenum glycinate, niacin, niacinamide, potassium chelate, pycnogenol, pyridoxine, riboflavin, thiamine, and zinc glycinate, wherein the composition is in therapeutically effective amounts to lower the plasma concentration of the lipoprotein Lp(a) in a mammal.

2. The method according to claim 1 , wherein the mammal is a human.

3. The method according to claims 1 or 2 , wherein the plasma concentration of the lipoprotein is lowered by at least 4%.

4. The method according to claims 1 or 2 , wherein the plasma concentration of the lipoprotein is lowered by at least 8%.

5. The method according to claims 1 or 2 , wherein the plasma concentration of the lipoprotein is lowered by at least 12%.

6. The method according to claim 1 , wherein ascorbic acid is 1,580 mg, niacin is 60 mg, lysine is 110 mg, and proline is 110 mg.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2009
From: SILICON VALLEY BANK
To: ARCTURUS BIOSCIENCE, INC.
Reel/Frame 023538/0140 →
SECURITY AGREEMENT Recorded Nov 29, 2005
From: ARCTURUS BIOSCIENCE, INC.
To: SILICON VALLEY BANK
Reel/Frame 017177/0060 →